AKP Stock Overview
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AKP from our risk checks.
Anika Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$23.40 |
52 Week High | US$26.40 |
52 Week Low | US$15.80 |
Beta | 0.75 |
1 Month Change | 2.63% |
3 Month Change | 14.71% |
1 Year Change | -10.00% |
3 Year Change | -26.88% |
5 Year Change | -13.14% |
Change since IPO | 383.03% |
Recent News & Updates
Recent updates
Shareholder Returns
AKP | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0.9% | 3.3% | 1.6% |
1Y | -10.0% | 35.8% | 6.4% |
Return vs Industry: AKP underperformed the German Biotechs industry which returned 35.3% over the past year.
Return vs Market: AKP underperformed the German Market which returned 6.4% over the past year.
Price Volatility
AKP volatility | |
---|---|
AKP Average Weekly Movement | 4.5% |
Biotechs Industry Average Movement | 5.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AKP has not had significant price volatility in the past 3 months.
Volatility Over Time: AKP's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1983 | 357 | Cheryl Blanchard | https://www.anika.com |
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief.
Anika Therapeutics, Inc. Fundamentals Summary
AKP fundamental statistics | |
---|---|
Market cap | €344.40m |
Earnings (TTM) | -€76.27m |
Revenue (TTM) | €153.76m |
2.2x
P/S Ratio-4.4x
P/E RatioIs AKP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AKP income statement (TTM) | |
---|---|
Revenue | US$166.66m |
Cost of Revenue | US$62.83m |
Gross Profit | US$103.84m |
Other Expenses | US$186.50m |
Earnings | -US$82.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -5.64 |
Gross Margin | 62.30% |
Net Profit Margin | -49.60% |
Debt/Equity Ratio | 0% |
How did AKP perform over the long term?
See historical performance and comparison